Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

201
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
201
Allergic Drug Reactions01:27

Allergic Drug Reactions

1.6K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.6K
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

260
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
260
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

219
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
219
Allergic Reactions02:06

Allergic Reactions

26.2K
Overview
26.2K
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

349
Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
349

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to Azacytidine in a Patient With Refractory Peripheral T-cell Lymphoma With TET2 Mutation.

Cureus·2024
Same author

Partial Response to Small Molecule Inhibition in a Case of Anaplastic Large Cell Lymphoma.

Cureus·2022
Same author

High Thermal Amplitude Red Blood Cell Agglutinating Cold Type Autoantibodies in a Case of Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia and Multiorgan Failure.

Journal of medical cases·2021
Same author

Severe bleeding after haemorrhoidal banding in a haemophilia patient treated with emicizumab.

Haemophilia : the official journal of the World Federation of Hemophilia·2021
Same author

Enfuvirtide-Induced Cutaneous Amyloidosis.

Cutis·2021
Same author

Pomalidomide and dexamethasone in myelomatous pleural effusion.

BMJ case reports·2020

Related Experiment Video

Updated: Apr 25, 2026

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response
06:31

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

8.2K

Severe dermatologic reactions with bendamustine: a case series.

Allison Carilli1, Gregory Favis2, Lohini Sundharkrishnan3

  • 1UF Health Cancer Center, Orlando Health, Orlando, Fla., USA.

Case Reports in Oncology
|August 15, 2014
PubMed
Summary

Cutaneous drug reactions are common adverse events. This study highlights rising skin reactions associated with bendamustine chemotherapy, aiding in the prevention of recurrent events.

Keywords:
Adverse eventsBendamustineChemotherapyDermatologic reactionLymphomaRash

More Related Videos

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

9.9K
Minimal Erythema Dose MED Testing
06:24

Minimal Erythema Dose MED Testing

Published on: May 28, 2013

42.1K

Related Experiment Videos

Last Updated: Apr 25, 2026

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response
06:31

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

8.2K
Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

9.9K
Minimal Erythema Dose MED Testing
06:24

Minimal Erythema Dose MED Testing

Published on: May 28, 2013

42.1K

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Cutaneous drug reactions represent a significant portion of adverse events in medicine.
  • Determining causality for these reactions is complex, complicating prevention strategies.
  • Bendamustine, a chemotherapy agent, was previously considered well-tolerated with minimal cutaneous side effects.

Observation:

  • The incidence of skin reactions linked to bendamustine is increasing.
  • Three distinct cases of cutaneous reactions following bendamustine administration are presented.
  • These observations suggest a potential underreporting of bendamustine-associated dermatologic toxicity.

Findings:

  • Bendamustine can cause various cutaneous adverse events.
  • Early recognition and reporting of these reactions are crucial for patient management.
  • The presented cases add to the growing body of evidence on bendamustine's dermatologic effects.

Implications:

  • Increased awareness among clinicians regarding bendamustine-induced skin reactions is necessary.
  • This can lead to improved diagnostic approaches and patient counseling.
  • Further research is warranted to elucidate the mechanisms and incidence of these reactions.